A number of other research analysts have also issued reports on the stock. Piper Jaffray Companies reiterated an “overweight” rating and set a $16.00 price target (up from $13.00) on shares of XBiotech in a research note on Wednesday, November 13th. ValuEngine cut shares of XBiotech from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Finally, Zacks Investment Research upgraded shares of XBiotech from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Thursday, November 21st.
Shares of XBIT opened at $10.91 on Wednesday. The stock has a market capitalization of $460.62 million, a P/E ratio of -18.49 and a beta of 0.46. The company’s fifty day moving average is $11.07 and its two-hundred day moving average is $8.88. XBiotech has a 1 year low of $4.10 and a 1 year high of $15.32.
Institutional investors and hedge funds have recently bought and sold shares of the company. Strs Ohio purchased a new stake in shares of XBiotech in the second quarter valued at approximately $357,000. JPMorgan Chase & Co. acquired a new stake in XBiotech in the second quarter valued at $34,000. Charles Schwab Investment Management Inc. acquired a new stake in XBiotech in the second quarter valued at $309,000. Bank of New York Mellon Corp lifted its holdings in XBiotech by 217.8% in the second quarter. Bank of New York Mellon Corp now owns 53,136 shares of the biopharmaceutical company’s stock valued at $403,000 after acquiring an additional 36,415 shares during the period. Finally, Northern Trust Corp boosted its position in shares of XBiotech by 72.5% during the 2nd quarter. Northern Trust Corp now owns 75,528 shares of the biopharmaceutical company’s stock worth $572,000 after purchasing an additional 31,752 shares in the last quarter. 11.96% of the stock is owned by institutional investors and hedge funds.
XBiotech Company Profile
XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.
Featured Story: What is a dividend reinvestment plan?
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.